Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)
A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects Following Laser-assisted in Situ Keratomileusis (LASIK)
Sponsor: Vance Thompson Vision ND
Listed as NCT05082974, this PHASE3 trial focuses on Dry Eye Disease and remains completed. Sponsored by Vance Thompson Vision ND, it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Not Yet Recruiting → Completed
-
Nov 2021 — Jul 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vance Thompson Vision ND
For direct contact, visit the study record on ClinicalTrials.gov .